SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chesnut C, Bell N, Clark G, Drinkwater B, English S, Johnston C, Notelovitz M, Rosen C, Cain D, Flessland K, Mallinak N 1997 Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102: 2937.
  • 2
    Garnero P, Shi W, Gineyts E, Karpt D, Delmas P 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79: 16931700.
  • 3
    Liberman U, Weiss S, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 14371443.
  • 4
    Delmas P, Bjarnason N, Mitlak B, Ravoux A, Shah A, Huster W, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 16411647.
  • 5
    Calvo M, Eyre D, Gundberg C 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17: 333338.
  • 6
    Hanson D, Weis M, Bollen A, Maslan S, Singer F, Eyre D 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7: 12511258.
  • 7
    Hanson D, Eyre D 1996 Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 271: 2650826516.
  • 8
    Bonde M, Qvist P, Fledelius C, Riss B, Christiansen C 1995 Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps®): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80: 864868.
  • 9
    Robins S, Woitge H, Hesley R, Ju J, Seyedin S, Seibel M 1994 Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9: 16431649.
  • 10
    Machado A, Hannon R, Eastell R 1999 Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14: 602608.
  • 11
    Clemens JD, Herrick M, Singer F, Eyre D 1997 Evidence that serum NTX (collagen type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43: 20582063.
  • 12
    Mallinak N, Pettinger, Cain D, Flessland K 1998 Serum NTX levels monitor hormone replacement therapy in early postmenopausal women. J Bone Miner Res 23(Suppl 5): F434.
  • 13
    Gertz G, Clemens JD, Holland S, Yuan W, Greenspan S 1998 Application of a new serum assay for type I collagen cross-linked N-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 63: 102106.
  • 14
    Scariano, J, Vanderjagt D, Thacher T, Isichei C, Hollis B, Glew R 1998 Calcium supplements increase the serum levels of crosslinked N-telopeptides of bone collagen and parathyroid hormone in rachitic Nigerian children. Clin Biochem 31: 421427.
  • 15
    Prestwood K, Thompson D, Kenny A, Seibel M, Pilbeam C, Raisz L 1999 Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 84: 179183.
  • 16
    Woitge H, Pecherstorfer M, Li Y, Keck A-V, Horn E, Zeigler R, Seibel M 1999 Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792801.
  • 17
    Willet WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witchi J, Hennekins CH, Speizer, FE. 1985 Reproducibility and validity of a semi-quantitative food frequency questionnaire. Am J Epidemiol 122: 5165.
  • 18
    Gertz B, Shao P, Hanson D, Quan H, Harris S, Genant H, Chesnut C, Eyre D 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9: 135142.
  • 19
    Fraser C 1992 Biological variation in clinical chemistry. An update: Collated data, 1988-1991. Arch Pathol Lab Med 116: 916923.
  • 20
    Greenspan S, Parker R, Ferguson L, Rosen H, Maitland-Ramsey L, Karpf D 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13: 14311438.
  • 21
    Greenspan S, Morgan J, Furstoss K, Rafferty J, Carpenter R, Pettinger M, Clemens J 1998 Measuring response to alendronate therapy in elderly women by serum cross-linked N-telopeptides (NTX) immunoassay. J Bone Miner Res 23(Suppl 5): SA431.
  • 22
    Hannon RA, Blumsohn A, Naylor K, Eastell R 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 13: 11241133.